Knowledge and perceptions about Cannabidiol use

Abstract

Background: Cannabidiol (CBD) is one of the main cannabinoids present in the cannabis plant. The demand for CBD grew over time with more individuals consuming CBD products due to its potential therapeutic properties. Objectives: To assess the knowledge and perceptions of Maltese members of the public and health care professionals (HCPs) about CBD, one of the main cannabinoids present in the cannabis plant. Methods: Surveys aiming to assess the knowledge and perception of the public and HCPs about CBD were developed, validated and disseminated. Results: Four hundred members of the public and 150 HCPs completed questionnaires. Ninety-six percent of participants (n=384) agreed that CBD has a therapeutic effect. Respondents from the general public were mostly knowledgeable about CBD and its use, had positive perceptions in relation to CBD and like HCPs, feel more comfortable if CBD is recommended by HCPs. HCPs were not so knowledgeable about certain aspects on CBD. One hundred and twelve HCPs were not aware that there is only one FDA/EMA approved CBD-based product. HCPs would feel comfortable in prescribing CBD products for pain and insomnia and the majority of them (55%; n=83) believe that CBD has mostly an analgesic effect. Social stigma associated with the use of CBD and potential judgement of HCPs were barriers to CBD use. Conclusion: Increased research, knowledge and availability of prescribing information and guidelines related CBD use might lead to an increased willingness of HCPs to recommend CBD and lead to a decrease in potential barriers associated with its use.


Keywords: Cannabidiol, positive perceptions, pain and insomnia

Keywords: Cannabidiol, positive perceptions, pain, insomnia

Downloads

Download data is not yet available.

Author Biographies

Abigail Calleja, Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Janis Vella Szijj, Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Anthony Serracino-Inglott, Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Lilian M. Azzopardi, Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

References

1. Szaflarski M, McGoldrick P, Currens L, Blodgett D, Land H, Szaflarski J et al. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists. Epilepsy Behav. 2020; 107102. https://doi.org/10.1016/j.yebeh.2020.107102 PMid:32442891
2. Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine. 2020;18(1):374. https://doi.org/10.1186/s12967-020-02518-2 PMid:33008420 PMCid:PMC7531079
3. García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020; 10(11): 1575. https://doi.org/10.3390/biom10111575 PMid:33228239 PMCid:PMC7699613
4. Gonçalves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC. Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant. Molecules. 2020; 25(7): 1567. https://doi.org/10.3390/molecules25071567 PMid:32235333 PMCid:PMC7181184
5. Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed Research International. 2018; 2018: 1691428. https://doi.org/10.1155/2018/1691428 PMid:30627539 PMCid:PMC6304621
6. Afrin F, Chi M, Eamens AL, Duchatel RJ, Douglas AM, Schneider J, et al. Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer. Cancers. 2020; 12(4): 1033. https://doi.org/10.3390/cancers12041033 PMid:32340151 PMCid:PMC7226605
7. Salami SA, Martinelli F, Giovino A, Bachari A, Arad N, Mantri N. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. Molecules. 2020; 25(18): 4036. https://doi.org/10.3390/molecules25184036 PMid:32899626 PMCid:PMC7571138
8. Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology. 2020;238(1):9-28. https://doi.org/10.1007/s00213-020-05712-8 PMid:33221931 PMCid:PMC7796924
9. Brunetti P, Lo Faro AF, Pirani F, Berretta P, Pacifici R, Pichini S, et al. Pharmacology and legal status of cannabidiol. Annali dell'Istituto Superiore di Sanità. 2020;56(3):285-91. doi: 10.4415/ANN_20_03_06
10. Kicman A, Toczek M. The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. Int J Mol Sci. 2020;21(18):6740. https://doi.org/10.3390/ijms21186740 PMid:32937917 PMCid:PMC7554803
11. Russo EB. Cannabidiol Claims and Misconceptions. Trends in Pharmacological Sciences. 2017;38(3):198-201. https://doi.org/10.1016/j.tips.2016.12.004 PMid:28089139
12. Huestis M.A, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò F.P. Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology. 2019; 17(10): 974-989. https://doi.org/10.2174/1570159X17666190603171901 PMid:31161980 PMCid:PMC7052834
13. Link K, Deshpande M, Ferguson M. Illinois Pharmacists and Over the Counter Cannabidiol Products: A Survey on Knowledge and Educational Needs. INNOVATIONS in pharmacy. 2020;11(2):2. https://doi.org/10.24926/iip.v11i2.2968 PMid:34007603 PMCid:PMC8051912
14. Wershoven N, Kennedy AG, MacLean CD. Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont. Journal of Primary Care & Community Health. 2020;11:215013272094695. https://doi.org/10.1177/2150132720946954 PMid:32757826 PMCid:PMC7412898
15. Leszko M, Meenrajan S. Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer's disease. Complementary Therapies in Medicine. 2021;57:102660. https://doi.org/10.1016/j.ctim.2021.102660 PMid:33418066
16. Hua DY, Lees R, Brosnan M, Freeman TP. Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a propensity score-matched analysis. BMJ Open. 2021;11(12):e053814. https://doi.org/10.1136/bmjopen-2021-053814 PMid:34916323 PMCid:PMC8685162
17. Schilling JM, Hughes CG, Wallace MS, Sexton M, Backonja M, Moeller-Bertram T. Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients' Perspectives and Attitudes. Journal of Pain Research. 2021;14:1241-1250. https://doi.org/10.2147/JPR.S278718 PMid:33981161 PMCid:PMC8107012
18. Malta Medicines Authority. Cannabis for medicinal and research purposes. 2023 [cited May 5 2023]. Available from: https://medicinesauthority.gov.mt/cannabisformedicinalandresearchpurposes?l=1#:~:text=In%202018%2C%20Malta%20enacted%20the,for%20medicinal%20and%20research%20purposes.
19. Bonnici J, Clark M. Maltese health and social wellbeing student knowledge, attitudes and beliefs about medicinal cannabis, Complementary Therapies in Medicine. 2021; 60: 102753. https://doi.org/10.1016/j.ctim.2021.102753 PMid:34139340
20. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for Reporting Qualitative Research: A Synthesis of Recommendations, Academic Medicine. 2014; 89:1245-1251. https://doi.org/10.1097/ACM.0000000000000388 PMid:24979285
21. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis and Cannabinoid Research. 2018;3(1):152-61. https://doi.org/10.1089/can.2018.0006 PMid:30014038 PMCid:PMC6043845
22. Lovecchio F, Langhans MT, Bennett T, Steinhaus M, Premkumar A, Cunningham M, et al. Prevalence of Cannabidiol Use in Patients With Spine Complaints: Results of an Anonymous Survey. International Journal of Spine Surgery. 2021;15(4):663-8. https://doi.org/10.14444/8087 PMid:34285125 PMCid:PMC8375682
23. Hammond D, Goodman S. Knowledge of tetrahydrocannabinol and cannabidiol levels among cannabis consumers in the United States and Canada. Cannabis and Cannabinoid Research. 2020; 7:3. https://doi.org/10.1089/can.2020.0092 PMid:33998866 PMCid:PMC9225412
24. Erridge S, Coomber R, Sodergren MH. Medical cannabis, CBD wellness products and public awareness of evolving regulation in the United Kingdom. Journal of Cannabis Research. 2022; 4:56. https://doi.org/10.1186/s42238-022-00165-6 PMCid:PMC9617440
25. Casanova C, Ramier C, Fortin D, Carrieri P, Mancini J, Barré T. Cannabidiol use and perceptions in France: a national survey. BMC Public Health. 2022; 22:1628. https://doi.org/10.1186/s12889-022-14057-0 PMid:36038869 PMCid:PMC9421113
26. Schmidt LA, Jacobs LM, Spetz J. Young people's more permissive views about marijuana: local impact of state laws or National Trend? Am J Public Health. 2016; 106: 1498-1503. https://doi.org/10.2105/AJPH.2016.303153 PMid:27196657 PMCid:PMC4940634
27. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708-9. https://doi.org/10.1001/jama.2017.11909 PMid:29114823 PMCid:PMC5818782
28. Mazzetti C, Ferri E, Pozzi M, Labra M. Quantification of the content of cannabidiol in commercially available e-liquids and studies on their thermal and photo-stability. Scientific Reports. 2021;11(1):16573. https://doi.org/10.1038/s41598-021-96039-7 PMid:34376801 PMCid:PMC8355102
29. Berg CJ, Getachew B, Pulvers K, Sussman S, Wagener TL, Meyers C, et al. Vape shop owners'/managers' attitudes about CBD, THC, and marijuana legal markets. Preventive Medicine Reports. 2020;20:101208. https://doi.org/10.1016/j.pmedr.2020.101208 PMid:32995147 PMCid:PMC7516178
30. Graham M, Bird S, Howard Z, Dobson M, Palazzi K, Lucas CJ et al. Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes, Internal Medicine Journal. 2022; 52:228-37. https://doi.org/10.1111/imj.15635 PMid:34837455 PMCid:PMC9304266
31. Hachem Y, Abdallah SJ, Rueda S, Wiese J, Mehra K, Rup J et al. Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices. BMC Complimentary Medicines and Therapy. 2022; 22: 237. https://doi.org/10.1186/s12906-022-03716-9 PMid:36076191 PMCid:PMC9453734
32. Garcia-Romeu A, Elmore J, Mayhugh RE, Schlienz NJ, Martin EL, Stickland JC et al. Online survey of medicinal cannabis users: qualitative analysis of patient-level data. Frontiers in Pharmacology. 2022; 13: 965535. https://doi.org/10.3389/fphar.2022.965535 PMid:36147312 PMCid:PMC9485457
33. Sabmeethavorn Q, Bonomo YA, Hallinan CM. Pharmacists' perceptions and experiences of medicinal cannabis dispensing: A narrative review with a systematic approach, International Journal of Pharmacy Practice. 2022; 30: 204-14. https://doi.org/10.1093/ijpp/riac005 PMid:35225341
34. Karanges EA, Suraev A, Elias N, Manocha R, McGregor IS. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. British Medical Journal Open. 2018;8(7):e022101. https://doi.org/10.1136/bmjopen-2018-022101 PMid:29970456 PMCid:PMC6042562
35. Rosenbaek F, Riisgaard H, Nielsen JB, Wehberg S, Waldorff FB, Pedersen LB et al. GPs' prescription patterns, experience and attitudes towards medicinal cannabis-a nationwide survey at the early stage of the Danish test scheme. BMC Primary Care. 2023;24:17. https://doi.org/10.1186/s12875-023-01971-4 PMid:36650442 PMCid:PMC9843989
36. Manoharan R, Kemper J, Young J. Exploring the medical cannabis prescribing behaviors of New Zealand physicians. Drug Alcohol Rev. 2022;1(6):1355-1366. https://doi.org/10.1111/dar.13476 PMid:35604868 PMCid:PMC9544511
37. Galea S, Zarb Adami M, Serracino-Inglott A, Azzopardi LM. Pharmacist interventions in non-prescription medicine use. Journal of Pharmaceutical Health Services Research. 2014; 5:55-9 https://doi.org/10.1111/jphs.12044
38. Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and Practices of Cannabis Dispensary Staff. Cannabis and Cannabinoid Research. 2016;1(1):244-51. https://doi.org/10.1089/can.2016.0024 PMid:28861496 PMCid:PMC5531366
39. Sharma P, Holland A, Sheikh T, Novy B, Oesterle T, Platt R et al. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innovation. 2022; 100044. https://doi.org/10.1016/j.pecinn.2022.100044 PMid:37213726 PMCid:PMC10194378
40. Dill J, Kurkowski A. CBD: Considerations for use within the health system. Hospital Pharmacy. 2020; 55(1): 9-11. https://doi.org/10.1177/0018578719873870 PMid:31983761 PMCid:PMC6961151
41. Moeller KE. McGuire JM, Melton BL. A nationwide survey of pharmacy students' knowledge and perceptions regarding medical cannabis. Journal of the American Pharmacists Association. 2020; 21-224. https://doi.org/10.1016/j.japh.2019.08.008 PMid:31585701
42. Felnhofer A, Kothgassner OD, Stoll A, Klier C. Knowledge about and attitudes towards medical cannabis among Austrian university students. Complementary therapies in medicine. 2021; 102700. https://doi.org/10.1016/j.ctim.2021.102700 PMid:33677020
43. Nichols MA, Arnett SJ, Fa B, Marchionda RA, Cutting MC, McDonald MR et al. National survey identifying community pharmacist preceptors' experience, knowledge, attitudes and behaviors influencing intent to recommend cannabidiol products. Journal of the American Pharmacists Association. 2021; S91-S104. https://doi.org/10.1016/j.japh.2021.01.016 PMid:33558186
44. Ukagbu O, Smith J, Hall D, Frain T, Abbasian C. Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK. Journal of Cannabis Research. 2021; 3:51. https://doi.org/10.1186/s42238-021-00104-x PMid:34906259 PMCid:PMC8672615
45. Hassan KM, Oluwafemi O, Ketchatang W. Pharmacy students' knowledge, attitudes and awareness toward marijuana use. J Pharm Pract. 2022; 36; 1170-76. https://doi.org/10.1177/08971900221096969 PMid:35475401
46. Sokratous S, Kaikoush K, Mpouzika MD, Alexandrou G, Karanikola NM. Attitudes, beliefs and knowledge about medical cannabis among nurses and midwives in Cyprus: a cross-sectional descriptive correlational study. BMC Nursing. 2022; 21: 120. https://doi.org/10.1186/s12912-022-00887-1 PMid:35585574 PMCid:PMC9118681
47. Jankie S, Sewdass K, Smith W, Naraynsingh C, Johnson J, Farnon N. A cross-sectional survey of prospective healthcare professionals' knowledge, attitudes and perceptions of medical Cannabis, Exploratory Research in Clinical and Social Pharmacy. 2023; 10: 100275. https://doi.org/10.1016/j.rcsop.2023.100275 PMid:37168830 PMCid:PMC10165452
Crossmark
Statistics
101 Views | 45 Downloads
How to Cite
1.
Calleja A, Szijj JV, Serracino-Inglott A, Azzopardi LM. Knowledge and perceptions about Cannabidiol use. JDDT [Internet]. 15Jan.2024 [cited 25Feb.2024];14(1):113-20. Available from: https://jddtonline.info/index.php/jddt/article/view/6266